Company intelligence / Profile preview
Exoxemis
Little Rock, Arkansas, United Statesexoxemis.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Exoxemis has primarily focused on the clinical development of its lead candidate E-101 (Zemyrox). The compound has completed Phase 2 clinical trials for the prevention of surgical site infections in patients undergoing major surgery. Results indicated that E-101 was well-tolerated and demonstrated a reduction in the incidence of infections compared to standard of care.
- Therapeutic areas
- Infectious Diseases
- Modalities
- EnzymeBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Exoxemis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exoxemis.